ESLOF:OTC-EssilorLuxottica Société anonyme (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 280

Change

+7.25 (+2.66)%

Market Cap

USD 128.93B

Volume

2.00

Analyst Target

USD 160.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-14 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

+0.20 (+0.14%)

USD 123.63B
HOCPF HOYA Corporation

+0.83 (+0.79%)

USD 36.78B
HOCPY Hoya Corp

+0.99 (+0.92%)

USD 36.78B
CLPBY Coloplast A

-0.11 (-1.04%)

USD 30.06B
TRUMF Terumo Corporation

-1.94 (-9.78%)

USD 27.92B
CLPBF Coloplast A/S

N/A

USD 23.07B
SRTOY Sartorius Stedim Biotech S.A

+0.51 (+2.32%)

USD 20.63B
SDMHF Sartorius Stedim Biotech S.A

+1.75 (+0.81%)

USD 19.85B
SAUHF Straumann Holding AG

-2.00 (-1.70%)

USD 17.44B
SOAGY Sartorius Aktiengesellschaft

-0.43 (-0.89%)

USD 16.51B

ETFs Containing ESLOF

C068:F 2.63 % 0.00 %

N/A

N/A
C068:XETRA 2.63 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.55% 77% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.55% 76% C+ 74% C
Trailing 12 Months  
Capital Gain 30.34% 92% A 80% B-
Dividend Return 1.98% 85% B 27% F
Total Return 32.32% 92% A 79% B-
Trailing 5 Years  
Capital Gain 141.38% 96% N/A 86% B+
Dividend Return 13.51% 88% B+ 31% F
Total Return 154.89% 94% A 83% B
Average Annual (5 Year Horizon)  
Capital Gain 16.23% 76% C+ 63% D
Dividend Return 17.93% 75% C 61% D-
Total Return 1.69% 59% D- 37% F
Risk Return Profile  
Volatility (Standard Deviation) 21.18% 89% A- 85% B
Risk Adjusted Return 84.63% 98% N/A 96% N/A
Market Capitalization 128.93B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.